Francis P. Worden, MD, provides background on the COSMIC-311 study, highlighting the methods and design utilized.
Videos
Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.
Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.
The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.
Anthony Hunter, MD, explains that anemia is a common complication in patients with myelofibrosis, often worsening over time; treatment strategies involve monitoring, transfusion support, and considering additional anemia-directed agents.
Mark Agulnik, MD, discusses advances in determining the molecular drivers of the tumor in the sarcoma space.
Mrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.
Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.
Mohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.
Abdulraheem Yacoub, MD, closes by sharing that the myelofibrosis treatment landscape is expected to evolve in the coming years with results to come from clinical trials investigating combination therapies, novel agents, and targeted approaches for disease progression and improving durability of response.
Severe anemia in myelofibrosis is defined as hemoglobin under 8 g/dL or transfusion dependence, requiring management with JAK inhibitors, erythropoietin stimulating agents, or danazol, given its impact on patient prognosis.
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.
Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.
Domenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.
The phase 3 DREAMseq trial compared initial treatments of combination immunotherapy or BRAF/MEK inhibitors for B-Raf mutated melanoma, showing a 20% overall survival benefit at 2 years for immunotherapy as the first-line treatment.
Momelotinib, a recently approved treatment for myelofibrosis, targets multiple pathways,and offers a promising approach to improve anemia, especially in patients who did not respond optimally to previous JAK inhibitors.
Hussein Tawbi, MD, PhD, explains that for BRAF-mutated metastatic melanoma, treatment options include checkpoint inhibitors, single-agent and combination IO therapies, and BRAF and MEK inhibitor combinations, offering varying response rates and progression-free survival periods.
Dr Anthony Hunter explains that the decision to initiate therapy in patients with myelofibrosis is individualized, considering factors like symptoms and risk stratification; early treatment with JAK inhibitors is crucial for symptom control, but allogeneic stem cell transplant remains the only potential curative therapy, particularly for higher-risk patients.
Nasir Chaudry, MD, discusses the significant advancements in the prostate cancer space in recent years.
Adam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma.
Ariel Lopez-Chavez, MD, discusses available frontline options for patients with small cell lung cancer, then moves into second-line treatments.
Clark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.
Carlos Rojas, MD, discusses preliminary findings from a phase 1 trial which of MK-1084 alone and with pembrolizumab in patients with advanced solid tumors and metastatic non–small cell lung cancer.
Dr Abdulraheem Yacoub discusses experience with the JAK inhibitor momelotinib in patients with myelofibrosis, noting robust efficacy in clinical trials for spleen volume reduction, symptom improvement, and anemia benefit, but explains that its utility in first-line versus second-line settings is still being determined.
Abdulraheem Yacoub, MD, reviews the current myelofibrosis treatment landscape including the four approved JAK inhibitors - ruxolitinib, fedratinib, pacritinib, and momelotinib - discussing the clinical trial data and indications for each in first-line and second-line settings.
Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.
Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer.
Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.
Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.
Thoracic medical oncologists discuss the evolving role of biomarkers in the non–small cell lung cancer treatment landscape.